ArticleTurkish journal of chemistry2026
Folic acid-targeted polymeric complex imprinted with doxorubicin and quercetin for controlled drug delivery in cancer therapy.
Article in Turkish journal of chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapy is often limited by the systemic toxicity and dose-dependent adverse effects of conventional chemotherapeutic agents such as doxorubicin (DOX). In this study, a folic acid-functionalized molecularly imprinted polymeric complex based on poly(HEMA) crosslinked with ethylene glycol dimethacrylate was synthesized for the controlled release of DOX in combination with quercetin (QUE), a flavonoid known for its antioxidant and chemosensitizing properties. The aim of this work was to develop and physicochemically characterize a preliminary targeted drug delivery platform at a material-design level. The polymeric complex was synthesized via free-radical polymerization following a DOX-QUE precomplex formation step. Structural characterization was performed using Fourier transform infrared (FTIR) and scanning electron microscopy (SEM) analyses. SEM micrographs revealed nanoscale spherical and partially aggregated polymeric domains, while FTIR spectra confirmed the successful incorporation of DOX, QUE, and folic acid into the poly(HEMA) matrix. In vitro release studies were conducted in 0.1 M acetate buffer at pH 5.5 to simulate mildly acidic tumor-relevant conditions. Within 180 min, measurable release was observed, with 0.0011 mg of DOX and 0.0978 mg of QUE released from the system. Thus, this study demonstrates the structural feasibility of a folic acid-functionalized imprinted polymer system capable of controlled release under acidic conditions, presenting a material-level physicochemical evaluation of a dual-drug imprinted polymeric platform. Biological validation, including cytotoxicity assays and receptor-mediated uptake studies, is not addressed in this study and remains necessary for comprehensive therapeutic assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.